All In Biotech

Drug Trial Radar · NCT01282619

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

A Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, Study to Evaluate the Safety and Efficacy of Huperzine A Sustained-Release Tablets in Patients With Mild to Moderate Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Jan 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 390 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

390

Planned (sponsor's estimate)

Start

May 2010

Primary completion

Jun 2012

Study completion Jun 2012

Sponsor

Sponsor type
Industry
First posted
Jan 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.

Conditions

  • Alzheimer's Disease

Interventions

  • Huperzine ADrug

    Sustained-Release Tablet, 400µg once a day, 24 weeks

  • huperzine ADrug

    Tablet, 200µg twice a day, 24 weeks

  • PlaceboDrug

    placebo orally twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale - Cognitive SubscaleTime frame: week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.